{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:01:56Z","timestamp":1792800116526,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072271"],"award-info":[{"award-number":["82072271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272319"],"award-info":[{"award-number":["82272319"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission","award":["2022-1-007"],"award-info":[{"award-number":["2022-1-007"]}],"id":[{"id":"https:\/\/ror.org\/0374a5s68","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission","award":["2022-2-018"],"award-info":[{"award-number":["2022-2-018"]}],"id":[{"id":"https:\/\/ror.org\/0374a5s68","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Climbing the peak (Dengfeng) Talent Training Program of Beijing Hospitals Authority","award":["DFL20191701"],"award-info":[{"award-number":["DFL20191701"]}]},{"name":"the Beijing Health Technologies Promotion Program","award":["BHTPP202002"],"award-info":[{"award-number":["BHTPP202002"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301900"],"award-info":[{"award-number":["2021YFC2301900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Beijing Key Laboratory for HIV\/AIDS Research","award":["BZ0089"],"award-info":[{"award-number":["BZ0089"]}]},{"name":"the Excellent Clinical Research Program in Research-Oriented Wards of Beijing Municipal Health Commission","award":["BRWEP2024W042180104"],"award-info":[{"award-number":["BRWEP2024W042180104"]}],"id":[{"id":"https:\/\/ror.org\/0374a5s68","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Owing to long-term antiretroviral therapy (ART), the incidence of non-HIV-related chronic diseases is increasing, and liver disease is the leading cause of increased AIDS mortality. Moreover, the prevalence of NAFLD and liver fibrosis has been reported to vary widely across regions and studies. There is no precise description of the trend and characteristics of NAFLD in PLWH. Here, we aimed to explore the prevalence and outcomes of NAFLD in people living with HIV (PLWH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PubMed, Web of Science, Embase, and Cochrane Library databases were searched on August 15, 2023, for studies that evaluated the prevalence of NAFLD or liver fibrosis among PLWH. The meta-synthesized effects of NAFLD and liver fibrosis were the primary outcomes, and potential moderators were the secondary outcomes. The meta-analysis of the combined event rate (ER) and random effects was conducted on the basis of the number of individuals with NAFLD, the number of individuals with liver fibrosis, and the total sample size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 3520 studies identified, 41 studies were eligible for the meta-analysis. The results revealed that the combined ERs of NAFLD and liver fibrosis were 0.38 (95% CI: 0.33\u20130.43,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and 0.25 (95% CI: 0.18\u20130.32,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This meta-analysis provided empirical evidence that the prevalence of NAFLD and liver fibrosis in PLWH is greater than that in the general population, which requires sufficient attention. In the HIV population, noninvasive imaging to monitor NAFLD changes should be strengthened, and a high TG level might be an early predictive indicator for HIV-associated fatty liver disease; however, large-scale prospective clinical research data are still needed for further validation and evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-10455-y","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T05:18:22Z","timestamp":1742361502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The prevalence of nonalcoholic fatty liver disease in people living with HIV: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiaqi","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"10455_CR1","unstructured":"https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics"},{"issue":"11","key":"10455_CR2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, Longenecker CT, Strachan F, Bagchi S, Whiteley W, et al. Global Burden of Atherosclerotic Cardiovascular Disease in people living with HIV: systematic review and Meta-analysis. Circulation. 2018;138(11):1100\u201312.","journal-title":"Circulation"},{"key":"10455_CR3","doi-asserted-by":"crossref","unstructured":"Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, G\u00fcnthard HF, Staehelin C, Zangerle R, Suarez I et al. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration. Clin Infect Dis 2024; 79(5):1242-1257.","DOI":"10.1093\/cid\/ciae228"},{"issue":"7","key":"10455_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S2468-1253(18)30077-3","volume":"3","author":"EA Tsochatzis","year":"2018","unstructured":"Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol. 2018;3(7):509\u201317.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10455_CR5","doi-asserted-by":"crossref","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020, 111s:154170.","DOI":"10.1016\/j.metabol.2020.154170"},{"issue":"3","key":"10455_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2468-1253(16)30120-0","volume":"2","author":"EC Verna","year":"2017","unstructured":"Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol. 2017;2(3):211\u201323.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10455_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"5","key":"10455_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/QAI.0b013e318198a88a","volume":"50","author":"N Crum-Cianflone","year":"2009","unstructured":"Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, Goodman Z, Parker R, Lifson A, Capozza T, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50(5):464\u201373.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10455_CR9","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, et al. 2019 global NAFLD prevalence: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809\u2013e28172828.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10455_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1440-1746.2012.07264.x","volume":"28","author":"A Kasturiratne","year":"2013","unstructured":"Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N, Wickremasinghe AR, de Silva HJ. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol. 2013;28(1):142\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10455_CR11","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2337\/dc15-0140","volume":"38","author":"H Yamazaki","year":"2015","unstructured":"Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent Association between Improvement of Nonalcoholic Fatty Liver Disease and reduced incidence of type 2 diabetes. Diabetes Care. 2015;38(9):1673\u20139.","journal-title":"Diabetes Care"},{"issue":"4","key":"10455_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10455_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","volume":"256","author":"VG Agopian","year":"2012","unstructured":"Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, Zarrinpar A, Petrowsky H, Farmer D, Yersiz H, et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg. 2012;256(4):624\u201333.","journal-title":"Ann Surg"},{"issue":"5","key":"10455_CR14","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.25855","volume":"56","author":"LB Vanwagner","year":"2012","unstructured":"Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012;56(5):1741\u201350.","journal-title":"Hepatology"},{"issue":"1","key":"10455_CR15","doi-asserted-by":"publisher","first-page":"e0191985","DOI":"10.1371\/journal.pone.0191985","volume":"13","author":"A Benmassaoud","year":"2018","unstructured":"Benmassaoud A, Ghali P, Cox J, Wong P, Szabo J, Deschenes M, Osikowicz M, Lebouche B, Klein MB, Sebastiani G. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. PLoS ONE. 2018;13(1):e0191985.","journal-title":"PLoS ONE"},{"key":"10455_CR16","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.eclinm.2021.101116","volume":"40","author":"J Bischoff","year":"2021","unstructured":"Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, van Bremen K, Dold L, Rockstroh JK, Trebicka J. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine. 2021;40:101116.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10455_CR17","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1093\/cid\/ciaa430","volume":"71","author":"A Cervo","year":"2020","unstructured":"Cervo A, Milic J, Mazzola G, Schepis F, Petta S, Krahn T, Lebouche B, Deschenes M, Cascio A, Guaraldi G, et al. Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with Human Immunodeficiency Virus. Clin Infect Dis. 2020;71(10):e694\u2013701.","journal-title":"Clin Infect Dis"},{"key":"10455_CR18","doi-asserted-by":"crossref","unstructured":"de Almeida CF, da Silva PS, Cardoso CSA, Moreira NG, Antunes JC, de Andrade MM, Silva J, Araujo MC, Peres WAF, do Brasil P et al. Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV. Nutrients 2021, 13(10).","DOI":"10.3390\/nu13103462"},{"issue":"2","key":"10455_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1086\/589294","volume":"47","author":"G Guaraldi","year":"2008","unstructured":"Guaraldi G, Squillace N, Stentarelli C, Orlando G, D\u2019Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47(2):250\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10455_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/0956462420960997","volume":"32","author":"T Jongraksak","year":"2021","unstructured":"Jongraksak T, Sobhonslidsuk A, Jatchavala J, Warodomwichit D, Kaewduang P, Sungkanuparph S. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people. Int J STD AIDS. 2021;32(3):266\u201375.","journal-title":"Int J STD AIDS"},{"issue":"4","key":"10455_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/QAI.0000000000002359","volume":"84","author":"A Kaplan","year":"2020","unstructured":"Kaplan A, Simon TG, Henson JB, Wang T, Zheng H, Osganian SA, Rosenblatt R, Lake J, Corey KE. Brief report: relationship between nonalcoholic fatty liver Disease and Cardiovascular Disease in persons with HIV. J Acquir Immune Defic Syndr. 2020;84(4):400\u20134.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"14","key":"10455_CR22","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1097\/QAD.0000000000001587","volume":"31","author":"M Lemoine","year":"2017","unstructured":"Lemoine M, Lacombe K, Bastard JP, Sebire M, Fonquernie L, Valin N, Fellahi S, Capeau J, Girard PM, Meynard JL. Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients. AIDS. 2017;31(14):1955\u201364.","journal-title":"AIDS"},{"issue":"6","key":"10455_CR23","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/jgh.15320","volume":"36","author":"D Liu","year":"2021","unstructured":"Liu D, Shen Y, Zhang R, Xun J, Wang J, Liu L, Steinhart C, Chen J, Lu H. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. J Gastroenterol Hepatol. 2021;36(6):1670\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"10455_CR24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.dld.2016.08.117","volume":"48","author":"R Lombardi","year":"2016","unstructured":"Lombardi R, Sambatakou H, Mariolis I, Cokkinos D, Papatheodoridis GV, Tsochatzis EA. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver Dis. 2016;48(12):1471\u20137.","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10455_CR25","doi-asserted-by":"publisher","first-page":"e2184","DOI":"10.1093\/cid\/ciaa1302","volume":"73","author":"JB Maurice","year":"2021","unstructured":"Maurice JB, Goldin R, Hall A, Price JC, Sebastiani G, Morse CG, Prat LI, Perazzo H, Garvey L, Ingiliz P, et al. Increased body Mass Index and Type 2 diabetes are the main predictors of nonalcoholic fatty liver Disease and Advanced Fibrosis in Liver biopsies of patients with Human Immunodeficiency Virus Monoinfection. Clin Infect Dis. 2021;73(7):e2184\u201393.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10455_CR26","doi-asserted-by":"publisher","first-page":"e0462","DOI":"10.1097\/MD.0000000000010462","volume":"97","author":"R Mohr","year":"2018","unstructured":"Mohr R, Boesecke C, Dold L, Schierwagen R, Schwarze-Zander C, Wasmuth JC, Weisensee I, Rockstroh JK, Trebicka J. Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. Med (Baltim). 2018;97(17):e0462.","journal-title":"Med (Baltim)"},{"issue":"1","key":"10455_CR27","doi-asserted-by":"publisher","first-page":"e87596","DOI":"10.1371\/journal.pone.0087596","volume":"9","author":"T Nishijima","year":"2014","unstructured":"Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Nozaki Y, Nagata N, Kikuchi Y, Yanase M, Oka S. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PLoS ONE. 2014;9(1):e87596.","journal-title":"PLoS ONE"},{"issue":"4","key":"10455_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2174\/1570162X19666210225085002","volume":"19","author":"MF Pezzini","year":"2021","unstructured":"Pezzini MF, Cheinquer H, de Araujo A, Schmidt-Cerski CT, Sprinz E, Herz-Wolff F, Poeta J. Transient Elastography in HIV infected patients with liver steatosis identifies a high-risk group for Non-alcoholic Steatohepatitis. Curr HIV Res. 2021;19(4):311\u20136.","journal-title":"Curr HIV Res"},{"issue":"4","key":"10455_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/QAI.0000000000001942","volume":"80","author":"L Iogna Prat","year":"2019","unstructured":"Iogna Prat L, Roccarina D, Lever R, Lombardi R, Rodger A, Hall A, Luong TV, Bhagani S, Tsochatzis EA. Etiology and severity of Liver Disease in HIV-Positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies. J Acquir Immune Defic Syndr. 2019;80(4):474\u201380.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10455_CR30","doi-asserted-by":"publisher","first-page":"ofz468","DOI":"10.1093\/ofid\/ofz468","volume":"6","author":"JC Price","year":"2019","unstructured":"Price JC, Wang R, Seaberg EC, Brown TT, Budoff MJ, Kingsley LA, Palella FJ Jr., Witt MD, Post WS, Lake JE, et al. Sex hormone-binding globulin levels are inversely Associated with nonalcoholic fatty liver disease in HIV-Infected and -uninfected men. Open Forum Infect Dis. 2019;6(12):ofz468.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10455_CR31","doi-asserted-by":"publisher","first-page":"ofx153","DOI":"10.1093\/ofid\/ofx153","volume":"4","author":"JC Price","year":"2017","unstructured":"Price JC, Wang R, Seaberg EC, Budoff MJ, Kingsley LA, Palella FJ, Witt MD, Post WS, Thio CL. The Association of inflammatory markers with nonalcoholic fatty liver Disease differs by Human Immunodeficiency Virus Serostatus. Open Forum Infect Dis. 2017;4(3):ofx153.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10455_CR32","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1080\/09540121.2016.1191603","volume":"28","author":"NF Shur","year":"2016","unstructured":"Shur NF, Tan Y, Goubet S, Fisher M, Gilleece Y, Verma S. Non-viral liver disease burden in HIV-monoinfected individuals: a longitudinal observational retrospective cohort study. AIDS Care. 2016;28(12):1522\u20137.","journal-title":"AIDS Care"},{"issue":"5","key":"10455_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/aid.2020.0177","volume":"37","author":"JH Sim","year":"2021","unstructured":"Sim JH, Sherman JB, Stanley TL, Corey KE, Fitch KV, Looby SE, Robinson JA, Lu MT, Burdo TH, Lo J. Pro-inflammatory Interleukin-18 is Associated with hepatic steatosis and elevated liver enzymes in people with HIV Monoinfection. AIDS Res Hum Retroviruses. 2021;37(5):385\u201390.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"17","key":"10455_CR34","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1097\/QAD.0000000000001241","volume":"30","author":"E Vuille-Lessard","year":"2016","unstructured":"Vuille-Lessard E, Lebouche B, Lennox L, Routy JP, Costiniuk CT, Pexos C, Giannakis A, Szabo J, Klein MB, Sebastiani G. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS. 2016;30(17):2635\u201343.","journal-title":"AIDS"},{"issue":"1","key":"10455_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.4102\/sajhivmed.v20i1.968","volume":"20","author":"M Vujanovi\u0107","year":"2019","unstructured":"Vujanovi\u0107 M, Brki\u0107-Jovanovi\u0107 N, Ili\u0107 D, Drvend\u017eija Z, Srdi\u0107-Gali\u0107 B, Turkulov V, Brki\u0107 S, Mari\u0107 D. Associations of visceral fat thickness and anthropometric measurements with non-alcoholic fatty liver disease development in male patients mono-infected with human immunodeficiency virus. South Afr J HIV Med. 2019;20(1):968.","journal-title":"South Afr J HIV Med"},{"issue":"6","key":"10455_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/hiv.13060","volume":"22","author":"C Yanavich","year":"2021","unstructured":"Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, Santos R, Morata M, Veloso VG, Grinsztejn B, et al. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and\/or advanced liver fibrosis in people living with HIV. HIV Med. 2021;22(6):445\u201356.","journal-title":"HIV Med"},{"issue":"3","key":"10455_CR37","first-page":"E219","volume":"58","author":"A Zizza","year":"2017","unstructured":"Zizza A, Guido M, Tumolo MR, De Donno A, Bagordo F, Grima P. Atherosclerosis is associated with a higher risk of hepatic steatosis in HIV-infected patients. J Prev Med Hyg. 2017;58(3):E219\u201324.","journal-title":"J Prev Med Hyg"},{"issue":"2","key":"10455_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/hep.22665","volume":"49","author":"P Ingiliz","year":"2009","unstructured":"Ingiliz P, Valantin M-A, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lomb\u00e8s A, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009;49(2):436\u201342.","journal-title":"Hepatology"},{"key":"10455_CR39","doi-asserted-by":"crossref","unstructured":"Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM, Abu-Asab M, Orenstein A, Engle RE, Hu X et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-Monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis 2015; 60(10):1569-78.","DOI":"10.1093\/cid\/civ101"},{"issue":"4","key":"10455_CR40","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/apt.13052","volume":"41","author":"I Vodkin","year":"2015","unstructured":"Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41(4):368\u201378.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10455_CR41","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/cid\/ciaa382","volume":"72","author":"LT Fourman","year":"2021","unstructured":"Fourman LT, Stanley TL, Zheng I, Pan CS, Feldpausch MN, Purdy J, Aepfelbacher J, Buckless C, Tsao A, Corey KE, et al. Clinical predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus\u2013Associated nonalcoholic fatty liver disease. Clin Infect Dis. 2021;72(12):2087\u201394.","journal-title":"Clin Infect Dis"},{"key":"10455_CR42","doi-asserted-by":"crossref","unstructured":"Riebensahm C, Berzigotti A, Surial B, G\u00fcnthard HF, Tarr PE, Furrer H, Rauch A, Wandeler G. Factors Associated with Liver steatosis in people with human immunodeficiency virus on contemporary antiretroviral therapy. Open Forum Infect Dis 2022, 9(11).","DOI":"10.1093\/ofid\/ofac538"},{"key":"10455_CR43","doi-asserted-by":"crossref","unstructured":"Ba\u015faran N\u00c7, \u0130dilman \u0130, Altunay H, Onur MR, S\u00f6nmezer M\u00c7, \u00d6z\u0131\u015f\u0131k L, Kar\u00e7aalt\u0131ncaba M, \u0130nkaya A\u00c7, \u00dcnal S. Detection of non-alcoholic fatty liver disease with non-invasive tools in Turkish people living with HIV and with apparently normal liver function. Curr HIV Res 2023;21(3):192-201.","DOI":"10.2174\/1570162X21666230714122716"},{"key":"10455_CR44","doi-asserted-by":"crossref","unstructured":"Han WM, Apornpong T, Lwin HMS, Thammapiwan S, Boonrungsirisap J, Gatechompol S, Ubolyam S, Tangkijvanich P, Kerr SJ, Avihingsanon A. Nonalcoholic fatty liver Disease and Nonalcoholic Steatohepatitis with Liver Fibrosis as predictors of New-Onset Diabetes Mellitus in people Living with Human Immunodeficiency Virus: a longitudinal cohort study. Clinical Infectious Diseases; 2023.","DOI":"10.1093\/cid\/ciad433"},{"key":"10455_CR45","doi-asserted-by":"crossref","unstructured":"Sebastiani G, Paisible N, Costiniuk C, Cox J, Kablawi D, Klein MB, Kronfli N, Routy J-P, Falutz J, Lebouch\u00e9 B et al. The relationship between visceral adiposity and nonalcoholic fatty liver Disease diagnosed by controlled attenuation parameter in people with HIV: a pilot study. Diagnostics 2022, 12(11).","DOI":"10.3390\/diagnostics12112590"},{"issue":"3","key":"10455_CR46","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cgh.2022.03.048","volume":"21","author":"M Lemoine","year":"2023","unstructured":"Lemoine M, Assoumou L, Girard P-M, Valantin MA, Katlama C, De Wit S, Campa P, Rougier H, Meynard J-L, Necsoi C, et al. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European Multicenter prospective study. Clin Gastroenterol Hepatol. 2023;21(3):713\u2013e722713.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10455_CR47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/infdis\/jiz096","volume":"220","author":"JA Aepfelbacher","year":"2019","unstructured":"Aepfelbacher JA, Balmaceda J, Purdy J, Mattingly A, Zambell K, Hawkins K, Chairez C, Curl KA, Dee N, Hadigan C. Increased prevalence of hepatic steatosis in young adults with lifelong HIV. J Infect Dis. 2019;220(2):266\u20139.","journal-title":"J Infect Dis"},{"key":"10455_CR48","doi-asserted-by":"crossref","unstructured":"Lombardi R. Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. Annals Gastroenterol. 2017;30(3):349-356.","DOI":"10.20524\/aog.2017.0141"},{"issue":"13","key":"10455_CR49","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1097\/QAD.0000000000002650","volume":"34","author":"J Milic","year":"2020","unstructured":"Milic J, Menozzi V, Schepis F, Malagoli A, Besutti G, Franconi I, Raimondi A, Carli F, Mussini C, Sebastiani G, et al. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. Aids. 2020;34(13):1915\u201321.","journal-title":"Aids"},{"key":"10455_CR50","doi-asserted-by":"crossref","unstructured":"De A, Duseja A, Badhala P, Taneja S, Sharma A, Arora S. Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease. Diabetes Metabolic Syndrome: Clin Res Reviews 2022, 16(12).","DOI":"10.1016\/j.dsx.2022.102679"},{"issue":"8","key":"10455_CR51","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/cid\/ciz435","volume":"70","author":"H Yki-J\u00e4rvinen","year":"2020","unstructured":"Yki-J\u00e4rvinen H, Sutinen J, Lundbom N, Hakkarainen A, Luukkonen PK, Isokuortti E, Lallukka-Br\u00fcck S. Natural course of nonalcoholic fatty liver disease and type 2 diabetes in patients with Human Immunodeficiency Virus with and without combination antiretroviral therapy\u2013associated Lipodystrophy: a 16-Year follow-up study. Clin Infect Dis. 2020;70(8):1708\u201316.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10455_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/apt.13702","volume":"44","author":"G Lui","year":"2016","unstructured":"Lui G, Wong VWS, Wong GLH, Chu WCW, Wong CK, Yung IMH, Wong RYK, Yeung SL, Yeung DKW, Cheung CSK, et al. Liver fibrosis and fatty liver in Asian HIV-infected patients. Aliment Pharmacol Ther. 2016;44(4):411\u201321.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10455_CR53","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1002\/hep4.2000","volume":"6","author":"G Villa","year":"2022","unstructured":"Villa G, Owusu D, Smith C, Azumah M, Abdullahi A, Phillips S, Sayeed L, Austin H, Chadwick D, Phillips RO, et al. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatol Commun. 2022;6(11):3036\u201351.","journal-title":"Hepatol Commun"},{"issue":"8","key":"10455_CR54","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/infdis\/jiaa246","volume":"222","author":"DM Kirkegaard-Klitbo","year":"2020","unstructured":"Kirkegaard-Klitbo DM, Fuchs A, Stender S, Sigvardsen PE, K\u00fchl JT, Kofoed KF, K\u00f8ber L, Nordestgaard BG, Bendtsen F, Mocroft A, et al. Prevalence and risk factors of moderate-to-severe hepatic steatosis in human immunodeficiency virus infection: the Copenhagen Co-morbidity Liver Study. J Infect Dis. 2020;222(8):1353\u201362.","journal-title":"J Infect Dis"},{"issue":"4","key":"10455_CR55","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/apt.13889","volume":"45","author":"S Petta","year":"2017","unstructured":"Petta S, Ciminnisi S, Di Marco V, Cabibi D, Camm\u00e0 C, Licata A, Marchesini G, Crax\u00ec A. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;45(4):510\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10455_CR56","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1111\/liv.12809","volume":"35","author":"F Shen","year":"2015","unstructured":"Shen F, Zheng RD, Shi JP, Mi YQ, Chen GF, Hu X, Liu YG, Wang XY, Pan Q, Chen GY, et al. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver Int. 2015;35(11):2392\u2013400.","journal-title":"Liver Int"},{"issue":"1","key":"10455_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4093\/dmj.2019.0011","volume":"43","author":"YH Lee","year":"2019","unstructured":"Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis. Diabetes Metab J. 2019;43(1):31\u201345.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"10455_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/j.gastro.2017.03.005","volume":"153","author":"P Nasr","year":"2017","unstructured":"Nasr P, Forsgren MF, Ignatova S, Dahlstr\u00f6m N, Cedersund G, Leinhard OD, Nor\u00e9n B, Ekstedt M, Lundberg P, Kechagias S. Using a 3% Proton Density Fat Fraction as a cut-off value increases sensitivity of detection of hepatic steatosis, based on results from histopathology analysis. Gastroenterology. 2017;153(1):53\u2013e5557.","journal-title":"Gastroenterology"},{"issue":"5","key":"10455_CR59","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.28012","volume":"62","author":"P Bannas","year":"2015","unstructured":"Bannas P, Kramer H, Hernando D, Agni R, Cunningham AM, Mandal R, Motosugi U, Sharma SD, del Munoz A, Fernandez L, et al. Quantitative magnetic resonance imaging of hepatic steatosis: validation in ex vivo human livers. Hepatology. 2015;62(5):1444\u201355.","journal-title":"Hepatology"},{"issue":"5","key":"10455_CR60","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/nu5051544","volume":"5","author":"M Gaggini","year":"2013","unstructured":"Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544\u201360.","journal-title":"Nutrients"},{"issue":"2","key":"10455_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11904-017-0351-2","volume":"14","author":"JK Rockstroh","year":"2017","unstructured":"Rockstroh JK. Non-alcoholic fatty liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) in HIV. Curr HIV\/AIDS Rep. 2017;14(2):47\u201353.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"10455_CR62","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/jac\/dky145","volume":"73","author":"DR Bakal","year":"2018","unstructured":"Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso SW, Veloso VG, Lake JE, Grinsztejn B. Obesity following ART initiation is common and influenced by both traditional and HIV-\/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177\u201385.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10455_CR63","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/aid.2012.0234","volume":"29","author":"W Lakey","year":"2013","unstructured":"Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses. 2013;29(3):435\u201340.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"11","key":"10455_CR64","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","volume":"31","author":"JB Maurice","year":"2017","unstructured":"Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. Aids. 2017;31(11):1621\u201332.","journal-title":"Aids"},{"issue":"4","key":"10455_CR65","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/hiv.13009","volume":"22","author":"A Hanttu","year":"2021","unstructured":"Hanttu A, Kauppinen KJ, Kivel\u00e4 P, Ollgren J, Jousilahti P, Liitsola K, Koponen P, Sutinen J. Prevalence of obesity and disturbances in glucose homeostasis in HIV-infected subjects and general population - missed diagnoses of diabetes? HIV Med. 2021;22(4):244\u201353.","journal-title":"HIV Med"},{"issue":"7","key":"10455_CR66","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/hiv.12843","volume":"21","author":"E Russell","year":"2020","unstructured":"Russell E, Albert A, C\u00f4t\u00e9 H, Hsieh A, Nesbitt A, Campbell AR, Maan EJ, Brophy J, Pick N, Murray M. Rate of dyslipidemia higher among women living with HIV: a comparison of metabolic and cardiovascular health in a cohort to study aging in HIV. HIV Med. 2020;21(7):418\u201328.","journal-title":"HIV Med"},{"key":"10455_CR67","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/CIA.S295524","volume":"16","author":"SA Alqahtani","year":"2021","unstructured":"Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging. 2021;16:1633\u201349.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"10455_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40121-018-0229-7","volume":"8","author":"BJ van Welzen","year":"2019","unstructured":"van Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A review of non-alcoholic fatty liver disease in HIV-Infected patients: the Next Big Thing? Infect Dis Ther. 2019;8(1):33\u201350.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10455_CR69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.antiviral.2009.09.014","volume":"85","author":"T Cihlar","year":"2010","unstructured":"Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 2010;85(1):39\u201358.","journal-title":"Antiviral Res"},{"issue":"1","key":"10455_CR70","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","volume":"10","author":"AM Margolis","year":"2014","unstructured":"Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10(1):26\u201339.","journal-title":"J Med Toxicol"},{"issue":"5","key":"10455_CR71","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u201354.","journal-title":"Hepatology"},{"issue":"4","key":"10455_CR72","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jhep.2017.05.011","volume":"67","author":"T Pembroke","year":"2017","unstructured":"Pembroke T, Deschenes M, Lebouch\u00e9 B, Benmassaoud A, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV\/HCV co-infected patients and is associated with liver fibrosis. J Hepatol. 2017;67(4):801\u20138.","journal-title":"J Hepatol"},{"issue":"2","key":"10455_CR73","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, et al. Liver fibrosis, but No other histologic features, is Associated with Long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389\u2013e397310.","journal-title":"Gastroenterology"},{"issue":"8","key":"10455_CR74","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, et al. Efficacy and safety of switching to Dolutegravir\/Lamivudine fixed-dose 2-Drug regimen vs continuing a Tenofovir Alafenamide-based 3- or 4-Drug regimen for maintenance of Virologic Suppression in adults living with human immunodeficiency virus type 1: phase 3, Randomized, Noninferiority TANGO Study. Clin Infect Dis. 2020;71(8):1920\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10455_CR75","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1097\/QAD.0000000000002644","volume":"34","author":"L Assoumou","year":"2020","unstructured":"Assoumou L, Racine C, Fellahi S, Lamaziere A, Farabos D, Beniguel L, Bastard JP, Feve B, Gibowski S, Katlama C, et al. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir\/etravirine. Aids. 2020;34(12):1859\u201362.","journal-title":"Aids"},{"key":"10455_CR76","doi-asserted-by":"crossref","unstructured":"Ngono Ayissi K, Gorwood J, Le Pelletier L, Bourgeois C, Beaup\u00e8re C, Auclair M, Foresti R, Motterlini R, Atlan M, Barrail-Tran A et al. Inhibition of adipose tissue beiging by HIV integrase inhibitors, Dolutegravir and Bictegravir, is Associated with Adipocyte Hypertrophy, Hypoxia, elevated fibrosis, and Insulin Resistance in simian adipose tissue and human adipocytes. Cells 2022, 11(11).","DOI":"10.3390\/cells11111841"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10455-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:56:40Z","timestamp":1743487000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10455-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10455"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10455-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study is based on published research and does not contain data from any individual person. Therefore, the consent for publication is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"239"}}